ArticleTherapeutic advances in musculoskeletal disease2026
Dipeptidyl peptidase-4 inhibitors are associated with a lower risk of osteoarthritis in patients with type 2 diabetes.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is the most prevalent form of arthritis. Currently, no disease-modifying OA drugs are available. Increasing interest has focused on repurposing antidiabetic medications to prevent OA. Preclinical studies showed that dipeptidyl-peptidase 4 inhibitors (DPP-4is) may protect against cartilage degeneration via anti-inflammatory and anti-senescent mechanisms. Objectives: To evaluate whether DPP-4i use is associated with a decreased risk of incident OA and joint replacement in patients with type 2 diabetes mellitus (T2DM). Design: A nationwide, population-based, matched new-user, retrospective cohort study. Methods: Using Taiwan's National Health Insurance Research Database (2008-2018), adult patients with newly diagnosed T2DM prescribed with DPP-4is were matched 1:1 to non-users based on age, sex, index year, and Diabetes Complications and Severity Index score. The primary endpoint was incident OA, while the secondary endpoints were total hip replacement (THR) and total knee replacement (TKR) attributed to OA. Cox proportional hazards models were used to estimate the adjusted hazard ratio (aHR) for comorbidities and concurrent medications. Results: In a sample of 1,282,796 patients with newly diagnosed T2DM, 165,333 pairs were matched for treatment with or without DPP-4is. Among 165,333 matched pairs (mean age: 58.6 years; 56.2% male), DPP-4i use was associated with lower risks of OA (aHR: 0.42; 95% confidence interval (CI): 0.41-0.44), THR (aHR: 0.38; 95% CI: 0.30-0.48), and TKR (aHR: 0.42; 95% CI: 0.37-0.46), with benefits increasing with dosage. Moreover, DPP-4i use was associated with a significantly lower cumulative incidence of OA, THR, and TKR. Conclusion: In this first nationwide cohort study, DPP-4is were associated with decreased OA incidence and fewer joint replacement surgeries among patients with T2DM. These findings indicate the joint-protective effects of DPP-4is, highlighting their relevance to drug repurposing and clinical decision-making in patients at high risk of OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.